% 0期刊文章%一方Juanzhi % Patricia Coyle %费尔南多Dangond Ali Hassan % Choon Cha % %安东尼红色%弗里德曼标志% T没有证据表明复发患者的疾病活动女士用干扰素治疗Beta-1a SC tiw与干扰素Beta-1a IM qw:证据研究的亚组分析(P7.271) % D J神经病学2015% % P P7.271 % V 84% N % X 14补充目的:比较干扰素的疗效Beta-1a (IFNβ-1a) 44 mcg皮下注射(SC) 3 X /周与干扰素β-1a 30微克肌内(IM) 1 X /周的NEDA(没有疾病活动的证据)状态的事后亚组分析患者复发女士(RMS)的试验证据。首页背景:在证据,更多的病人仍无复发(主要结果衡量)/ 24周比干扰素干扰素β-1a SCβ-1a IM (75 vs 63 [percnt] [percnt], p < 0.001)。设计/方法:RMS患者随机分配到干扰素β-1a SC (n = 339)或干扰素β-1a IM (n = 338)。病人处理间差异达到NEDA状态(没有复发或蠅1点扩大残疾状态量表(eds)分数增加蠅持续12周,和没有新的/扩大T2病灶)进行评估的子组)基线eds≤> 2.0, b)有/没有高度活跃的疾病(蠅2在前一年复发),和c)蠅1钆增强病变在入口,和分层的其他特征。响应者措施与直接相关(前12周内)和延迟(12周)后响应和NEDA状态的相关性在24或48周预测未来发展正在评估。结果:患者接受干扰素β-1a SC更有可能比那些接受干扰素NEDA在24周β-1a IM,是否有基线eds≤2.0(优势比2.09[或][95 (percnt)置信区间1.35 - -3.25))或> 2.0 (1.86 [1.15—-2.99])。口服补液盐青睐干扰素β-1a SC在干扰素β-1a IM实现NEDA地位在所有子组24和48周。结论:患者的RMS,干扰素β-1a SC优于干扰素β-1a IM以实现NEDA地位,无论小组。研究支持:EMD Serono公司,大利好,美国(默克公司的子公司,达姆施塔特,德国)和辉瑞(pfe . n:行情),纽约,纽约,美国。披露:博士方已收到个人活动与EMD Serono补偿作为一个员工。Coyle博士已经收到个人活动与AbbVie补偿,谐调,Acorda,拜耳,生原体,EMD Serono, Inc .,基因泰克,Genzyme, Mylan,诺华和梯瓦公司担任顾问。 Dr. Hassan has received personal compensation for activities with EMD Serono as an employee. Dr. Cha has received personal compensation for activities with EMD Serono as an employee. Dr. Dangond has received personal compensation for activities with EMD Serono, Inc. an employee. Dr. Reder received personal compensation from Acorda Therapeutics, Inc., Bayer Pharmaceuticals Corporation, Biogen Idec, EMD Serono, Genzyme Corporation, Novartis, Pfizer Inc., Questcor, Sanofi-Aventis Pharmaceuticals, and Teva Neuroscience as a consultan Dr. Freedman has received personal compensation for activities with Bayer Healthcare, Biogen Idec, Chugai, EMD Canada, Genzyme, Novartis, Sanofi-Aventis, and Teva Canada Innovation.Thursday, April 23 2015, 2:00 pm-6:30 pm %U